Opendata, web and dolomites

REVERSEAUTISM SIGNED

Probing the Reversibility of Autism Spectrum Disorders by Employing in vivo and in vitro Models

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 REVERSEAUTISM project word cloud

Explore the words cloud of the REVERSEAUTISM project. It provides you a very rough idea of what is the project "REVERSEAUTISM" about.

autism    encoding    serum    employ    symptoms    slc7a5    hyper    functionally    elucidating    consequence    bcaa    biological    blood    metabolism    employing    bcaas    suggests    neurological    treat    biomarkers    sequencing    classified    chain    nature    converge    reverse    circuits    ing    dehydrogenase    therapeutic    2012    levels    stereotypical    reversible    strategies    poor    irreversible    individuals    mutations    ketoacid    implying    bckdk    potentially    direct    disorders    al    et    atypically    transporter    spectrum    shown    stem    maturation    human    molecular    forms    kinase    link    impairments    flux    defects    skills    genetic    homogenous    etiological    critical    group    form    gene    reinforces    causes    interaction    social    2014    branched    molecules    broad    novarino    mediating    science    barrier    prompt    acids    repetitive    possibility    preventable    amino    neural    employed    asd    communication    cell    genes    caused    heterogeneity    behaviours    organoids    clinical    cerebral    trial    genetically    exome    exploring    untangling    outcome    neurodevelopmental    pathology    cognition    brain    basis   

Project "REVERSEAUTISM" data sheet

The following table provides information about the project.

Coordinator
INSTITUTE OF SCIENCE AND TECHNOLOGY AUSTRIA 

Organization address
address: Am Campus 1
city: KLOSTERNEUBURG
postcode: 3400
website: www.ist.ac.at

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Total cost 1˙498˙394 €
 EC max contribution 1˙498˙394 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-STG
 Funding Scheme ERC-STG
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2022-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUTE OF SCIENCE AND TECHNOLOGY AUSTRIA AT (KLOSTERNEUBURG) coordinator 1˙498˙394.00

Map

 Project objective

Autism Spectrum Disorders (ASD) are a group of neurological conditions characterized by stereotypical or repetitive behaviours as well as impairments in social interaction and communication skills, often of genetic basis. ASD have been classified as neurodevelopmental disorders, implying irreversible defects in the maturation of neural circuits. We have shown that mutations in the Branched Chain Ketoacid Dehydrogenase Kinase (BCKDK) gene lead to a potentially preventable and reversible form of ASD (Novarino et al. Science 2012). The most direct consequence of BCKDK mutations is a hyper-metabolism of the branched chain amino acids (BCAAs), resulting in atypically low levels of serum and brain BCAAs. Recently, using whole exome sequencing we identified individuals with ASD carrying mutations in the gene SLC7A5, encoding for the transporter mediating BCAA flux across the blood brain barrier. This suggests that the BCAAs are critical for brain development and cognition and reinforces their link with ASD. The simple nature and availability of the BCAAs prompt raising the possibility that this group of amino acids may be employed to treat symptoms of other ASD. We aim at 1) elucidating the link between BCAAs, ASD, brain development and cognition; 2) exploring the possibility of employing the BCAAs to reverse symptoms caused by mutations of ASD-genes. The genetic analysis of ASD is untangling the etiological heterogeneity that may contribute to poor clinical trial outcome. However, recent studies, including our own (Novarino et al. Science 2014), show that genetic causes of neurological disorders converge along specific biological processes. Our third objective is to employ stem cell-derived human cerebral organoids to identify key molecular changes involved in the pathology of genetically distinct but functionally homogenous forms of ASD. These molecules may represent the target for future “broad spectrum” therapeutic strategies as well as potential biomarkers (aim 3).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REVERSEAUTISM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REVERSEAUTISM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

LO-KMOF (2019)

Vapour-deposited metal-organic frameworks as high-performance gap-filling dielectrics for nanoelectronics

Read More  

TRUST (2018)

Truth and Semantics

Read More  

PLAT_ACE (2019)

A new platform technology for the on-demand access to large acenes

Read More